Core Concept
Importance of new drug development based on clinically relevant biomarkers
Core Technology
CTA (Clinical-based Target for Antibody Drug) Platform for Efficient Drug Development
CTA Platform
Innovative R&D through precise assessment of target indication
-
C Clinical Unmet Need Based
New Drug DevelopmentClinically Needed Drug
- Pharmaceuticals Needed in Clinic
- Preemptive Clinical Trial Design
- Animal Studies that Mimic Clinical Trials
-
T Target Analysis Based
on Clinical DiseasesTherapeutic Target Selection
- Target Discovery from Patient Tissues
- Disease-Specific Target Analysis
- Target Identification through Drug Responsiveness Prediction
-
A Antibody Development
Antibody therapeutics
- High Affinity & Selectivity for the Target
- High Potency & Productivity
- Monoclonal, Bispecific antibodies, ADCs
-
Biomarker-based diagnostics and therapeutics
-
Animal Studies that Mimic Clinical Trials
-
Clinical Trial monitoring biomarker changes
Innovation
- Market-Leading New Drug
- Pipeline reinforcement
- Global Competitiveness
- Sustainable Growth